Regulation of biotechnology
• Biotechnology is in transition from a Iledgling science \0 an attractive business. and the fats and oils industry will face new challenges as biotechnology becomes pan of mainstream U.S. business operations. Developing regulations to effectively manage the new technologies is proving to be a major challenge to government agencies.
In the past decade U.S. biotech companies have invested billions of dollars in long-term research. Monsanto has successfully engineered a cotton variety to express a toxin to colton pests, and has engineered other oilseeds to tolerate a particular herbicide. Calgene has produced herbicidetolerant varieties of rapeseed and COlton. Agrigenetics has produced a variety of sunflower that has higher amounts of oleic acid.
The new oilseed varieties are not problem-free, however. The planned introduction of transgenic oilseed cruVln this section:
INFORM. Vol. 3. no. 3 (March 1992) (USDA) funds for agricullural biotech research will total $178 million in fiscal year 1992, according to Alvin Young of USDA's Office of Agricultural Biotechnology.
Governmentwide spending on biotech research is expected to total $3.78 billion in 1992.
Regulators are struggling to understand their responsibilities in what amounts 10 a tidal wave of innovations. Federal regulators seek to protect human safety, intellectual property rights of individuals and corporations, and the genetic integrity of existing plant and animal species. Government agencies also must take care not to so burden companies with unnecessary regulations that trade and innovation are discouraged. Biotechnology companies must conduct their work in accordance with often illdefined laws while protecting returns on their investments of lime and research dollars.
it' Current regulations
Current regulations are not clear. In July 1991, the U.S. Department of Agriculture'S APHIS held a conference on the subject of federal and state regulation of biotechnology. Terry Medley, Director of Biotechnology, Biologics, and Environmental Protection at APHIS, said that the task before government agencies is to remove existing regulatory uncertainty.
Effective regulations should facilitate the safe transfer of technology from laboratory to marketplace, Medley said, and should not only protect health and safety but also should encourage innovations-a challenge for government agencies facing decreasing funds and increasing workloads.
Biotechnology, and genetically engineered organisms, first received widespread legal anenuon in 1980 when the U.S. Supreme Court ruled that living organisms could be patented. Previously, patents were not permitted for living organisms on the grounds that these were "products of federal agency in biotechnology regulation.
Most of the USDA's regulation of plants is coordinated through APHIS. In 1987 the USDA issued a final rule governing the introduction of genetically engineered organisms which are or could become plant pests, as well as rules governing transportation of such organisms. In 1991 USDA issued proposed guidelines [or research involving the introduction into the environment of organisms with deliberately altered genetic traits. USDA also has published a document of "Points 10 Consider" when introducing genetically engineered organisms into the environment: these are nonmandatory guidelines for researchers. The guidelines are 10 be followed for USDA-sponsored research but are not intended to replace final regulations, said Lisa Zannoni. legal advisor to the U.S. Assistant Secretary for Science and Education. The USDA will expect institutions to certify that their guidelines are comparable in safety coverage to the USDA guides in order to receive USDA funding, she said.
"The goal of the guidelines and their implementation is to provide the public assurance that there is appropriate review consistent with the risk of the proposed research and to do so with the minimum workload." Zannoni said.
Current regulations require that APHIS issue a permit for the import, interstate movement, or release into the environment of a "regulated article," defined as "an organism that has been genetically engineered (via recombinant DNA techniques) from a donor organism. recipient organism. vector. or vector agent that is a plant pest or contains plant pest components."
"Plant pest" is a key phrase. For APHIS regulations to apply, some component of a plant pest must be involved. If the plant or organism is nature:' The court allowed the patent because biotechnology procedures had made possible a human invention from a naturally-occurring organism. The pivotal case, Diamond V.f
Chakrabarty. concerned a bacterium engineered to cal crude oil. Ensuing public concern focused not on the microbe but on the fact that it had been genetically altered by direct human intervention; much of that public alarm stili remains.
The Supreme Coun decision raised hopes among biotech researchers, then a relatively small group, that government agencies would soon follow with regulations that would foster the commercial development of engineered organisms. But the Environmental Protection Agency (EPA) has been very slow at issuing guidelines for large-scale release of genetically engineered microbes. Ten years later, at the time of the Exxon Valdez oil spill in Alaskan waters. no regulations were in place to permit the use of those organisms patented in 1980.
A number of federal agencies are involved in biotechnology regulation, including the USDA, the EPA, and the Food and Drug Admiuistrution (FDA). 11 hns sometimes proven difficult to know which agency held jurisdiction on matters of biotechnology, but a regulatory system is evolving. In 1986 a "Coordinated Framework" for federal regulation of biotechnology was announced.
The Coordinated Framework established that: (n) if the biotech product to be released was a microbe, EPA would regulate it (b) if the biotech product to be released was a plant or insect. USDA-APHIS would regulate it; (c) if the biotech product was a food or medicine, FDA would regulate it: and (d) if the research was funded by the federal government. the National Institutes of Health (NIH) or USDA would regulate the products of research.
USDA guidelines In the area of genetically engineered plants. the USDA is the most active and will also send copies of the proposal to affected state agencies to request their comments. APHIS is required to respond to the petitioner within 180 days of publication.
A final rule is published in the Federal Register, A petition 10 APHIS for the release of a regulated orgnnism must include extensive environmental analysis by the petitioner. APHIS also prepares its own environmental assessment.
APHIS inspects the test site near the beginning of the field lest, after the harvest, and possibly during the trials. As one permit application can be made for field tests in several states.
some companies cui down on the number of times they must pennon APHIS by drafting petitions that are vcry broad in scope. This is an area where the regulations are vague. Michael Lidsky. a deputy director of biotechnology, biologics. and environmental protection at APHIS, called the deci- (cofUi"u~dfrompog~243} classified as a nonpest, no regulation from APHIS is needed-although regulations from other agencies may apply.
The USDA has a fairly inclusive definition of a plant pest: roughly summarized. a plant pest is any organism. virus, infectious agent, or portion thereof (including active and dormant fonns) which can directly or indirectly harm any plant or plant part. including any products of a plant. such as seed.
A resulting organism will be regulated if a pest is used in any part of the genetic engineering process. Subsequent generations of the organism in question will also be subject to regulation.
A company wanting to commercialize its pest-containing transgenic plant variety. then, may seek a penni! from APHIS for field testing. or may seek exemption from regulation. To obtain a pennit for release of an organism into the environment. a company must follow federal procedurcs using "notice and comment" rulemaking. The company will send n proposal to APHIS. which publishes the proposal in the Federal Register. APHIS will solicit written comments and hold a hearing on the proposal. sion to submit broad petitions "a business decision." "There are no rules here." Lidsky said.
Permits have been issued for 15 crops. led by potato, com and tomato varieties.
"Cotton is coming on strong." said Arnold Foudin, deputy director of biotechnology, biologics. and environmental protection at APHIS. "Com. soybeans, and canol a are starting to make a show of it." he added.
To receive an exemption from the regulations. a company must provide APHIS with data and information 10 show that the organism in question is not a plant pest: this information must include copies of scientific literature and unpublished studies. data from tests performed. and also any unfavorable infonnation. In some cases a conditional exemption is granted in which the organism is permitted to be released under geographic restrictions.
Approval for transportation of a regulated article is simpler than Obtaining approval for intentional release. Interstate movement and import permits are issued within 60 days after APHIS receives an application. APHIS staff review the application and make a preliminary risk analysis, and state regulatory officials are allowed to review and respond to the application. If the facility receiving the regulated article has not been inspected previously by governmental officials. representatives from APHIS and the state agency will inspect the facility to verify it can prevent unintentional release of the organism. Transport permits are valid for one year.
The efficacy of current regulation depends on the integrity of persons conducting the experiments; this is seen as a regulatory weakness by some environmental groups. APHIS must be immediately notified if an accidental or unauthorized release occurs. followed by a written notification within 24 hours. APHIS must be notified within five days if me regulated article or associated organism is found to have characteristics differing significantly from those listed on the permit application, or to have an unexpected effect on other organisms.
New guidelines needed Officials from government agencies have expressed alarm at the vagueness of current regulations. Many agencies are calling for clearer guidelines to follow when making policy decisions.
IilStates' rights vs federal preemption: who's in charge?
One crucial factor in biotechnology regulation is stare legislation.
The development of state regulatory processes may significantly affect research, said warren Springer. former executive director of the Minnesota Biotechnology Association.
Even as federal agencies are generating policies 10 regulate biotechnology, some state agencies are esteblishing their own policies. In states thai are more active on the issue. regulations which they enact often are
When federal and stare regulations differ. which is to be enforced? In some states. traditional federal preemption of those stare regulations is being challenged.
In 1989. a Wisconsin municipality adopted an ordinance giving it the authority to regulate the local use of pesticides-anyone wishing to use a pesticide. even on a home lawn. has to register that use with the municipality. Under common interpretation of the Federal insecticide. Fungicide, and Rodenticide Act (FIFRA). the EPA regulations were assumed to preempt state and local regulations concerning pesticide use; FIFRA requires that states may not adopt regulations dramatically different from those of the EPA. The local ordinance in Wisconsin was dramatically different, and the ordinance was challenged in court. But in 1991. the U.S. Supreme Court ruled that AFRA does not give the EPA preemption over state and municipal regulations.
"1 see FIFRA as applying to biotechnology products also," Springer said. "and if the states want to write their own regulations. especially where pesticides are concerned. it looks as if they have the authority. "This lack of clear preemption authority by the federal government has the potential to be the biggest issue in biotechnology 10 date."
Federal authority is being challenged in other states as well. Minnesota passed a law in 1989 which requires thai a Slate permit be issued before any release of genetically engineered organisms. The Minnesota law does not recognize the federal regulatory system at all. Springer said. Permits are to be issued by the Minnesota Environmental Quality Board. which was essentially given statewide control of the permitting process. Smith commented that "States need to complement federal oversight. not add to it. We can't afford to add to it."
The biggest challenge for Smith's department in New Jersey is the lack of financial support. Tightening state budgets are making it difficult for agencies to keep up with the increasing workload as more companies and institutions seck to commercialize their innovations. Ccmmercializanon of biotech products could be affected by cuts in state budgets that affect biotechnologyconcerned agencies, Smith warned. New Jersey is second to California in Ihe number of biotech companies in the state, he said.
Commercialization
As biotech products reach commercialization. the need for clear and uniform regulations will become more urgent. Springer said the federal government has been reactive rather than leading in developing regulations. which has motivated states to become more active in developing their own regulations. Springer said it is crucial that the nation develop a uniform system of reg-regulations. Before companies may begin marketing engineered products in earnest, new regulations will be needed.
answers are needed for biotechnology to be managed efficiently.
To date, U.S. government agencies have taken a "risk-based" approach 10 the regulation of biotechnology: that is, they have focused on the end product of the biotechnology. and its risks, rather than the process by which it was created. The Bush administration. through the Office of Science and Technology Policy. has fostered this altitude toward biotechnology regulation. The office has urged federal agencies not 10 regulate genetically engineered organisms unless there is a "reasonable risk" to health and safety.
Greg Simon, former staff director of the subcommittee on investigations and oversight, Committee on Science, Space and Technology, described this "risk-based" attitude as "too little, too soon" in a letter published in the May 3. 1991, issue of Science.
"It is 'too little' because it mini- Funding is an important issue in Maine, where departmental funding has been cut substantially in recent years. Mosher said. The state's Commission on Biotechnology and Genetic Engineering currently has no budget; any work done is through staff "borrowed" from the Department of Agriculture. he said. The commission, established in 1989, is responsible for risk assessment and for developing and implementing biotech regulations.
States could pass legislation which would threaten commercialization of biotechnology products, Mosher said. A bill was introduced in Maine to ban the use of products made with bovine somatotrophin, a hormone that can be used to increase milk production in dairy cattle, he reponed.
Pesticidal plants, which are genetically engineered to contain toxins harmful to insects that feed on the plants, also present problems for state regulators, Mosher said. If the EPA is going to regulate these, then the enforcement procedure in the state would rely on the federal Board of Pesticide Control, even though the state has the Commission on Biotechnology and Genetic Engineering for such oversight. "Which board will have jurisdiction?" Mosher asked.
Tobi Jones, chief of the pesticide registration branch of the California Department of Food and Agriculture, said that further effects of state laws on biotech commercialization would depend on federal regulations.
"We're waiting on the EPA for regulating pesticidal plants," she said. "What aspects of plants will be regulated-c-rbe genes, gene products, seeds?" Under FIFRA, states are designated as primary enforcement agencies in partnership with the EPA, Jones said. If the EPA modifies its current labelling of pesticides, California will have to also, she said. Although the state doesn't require authorization for release of pesticidal plants. it does require authorization if pesticide use is involved.
Should these measures also be required with a pesticidal plant? "That's a puzzle." Jones said.
Food safety is also a big question. Mosher reported that food safety issues in Maine include the effect of biotechnology on the structure of agriculture. limitations to citizen right-to-know Jaws, the extent of public participation. and the role of the legislature to monitor food safety.
"Food safety appears to be the primary issue with regard 10 transgenic plants," Jones said. Her office is wailing for the FDA to make decisions on how it will regulate food safety with regard to transgenic plants. "Clear communication from the FDA will lessen the need for state regulation," Jones said. Currently much of the information received at the state level is through the Federal Register, she commented.
Perception leads regulation "What we're really dealing with is perception," Springer said. "Public policy is not based on fact as much as on perception, and that perception is still developing," he said. "It's a wide-open area, open to whoever is most aggressive to pushing their perspective. I don't want to suggest that one side is right and another wrong, but 10 say that choices in the political area are based on what people believe is the public perception.
"The upper hand appears to be on the side of those who see biotechnology as bad. Minnesota Biotechnology Association members are quick to support our state having the best safety net that can be developed, but how do we strike the balance between a net and a blanket?'"
Infonning the public is a task that is likely to fall to state agencies. To this end, Meagher stressed the need for two-way communication with various public groups through interactive, informal hearings.
"States are on the front line when it comes to dealing with the commercialization of biotechnology," she said.
• mizes consideration of ecological issues and overvalues the molecular biology approach to risk assessment of introduced organisms .... It is 'too soon' because it proposes a decentralized oversight of field trials before there is sufficient field trial data to support the model's assumptions and before the public has shown a willingness 10 accept self-regulation in the biotechnology industry," Simon said.
Government agencies have different ideas about risk. David Giamporcane. a lawyer working in the EPA Chemical Control Division, described several questions the EPA considers important in evaluating the risk of a proposed release. What is the effect of the genetic change? Are the strains well-characterized? What is the ability of the organism to persist in the environment (i.e.. dissemination and resistance)? What are the human health effects. including effects to workers? What are the environmental effect's? Overall. will the organism be beneficial?
Other regulators call for less cautious risk assessment. McCammon agreed thai regulation should be riskbased, but designed to protect the environment without unnecessary burden.
"Risk assessment is the probability of hazard limes the probability of exposure," she said. "We shouldn't assume a risk until one is demonstrated." Jim Lackey. a biotechnology safety officer at APHIS. said that the effects of introducing potentially invasive species into the U.S. are a big concern to APHIS. The United States has a history of problems with invasive plant species. he said. Canota. for example, has weedy relatives indigenous to the U.S., such as wild mustard. and could transfer genetic material to those relatives. Because herbicide-resistant canola could become a weed in fields where canola is rotated with crops such as corn, wheat, or soybeans. Du Pont has held back on commercializing its sulfonylurearesistant canota variety.
APHlS also is concerned that introduction of new plants could effect a reduction or alteration in the gene pool and genetic diversity of U.S. plant species, Lackey said. He used sunflower as an example. The United States is the germptasm base for sunflower, he said, and because cultivated sunflowers do cross with wild species, it is possible that a gene inserted into cultivated sunflower could move into wild relatives. Tomatoes, on the other hand. do not have any wild species in the United States and are not invasive, so they are not likely to exhibit genetic flow into other distinct species. lackey said. Soybeans are not indigenous to the United States either, he reported.
Lackey cited a need for established remedial measures and safeguards to keep control of the genetic mutations caused by deliberate engineering; keeping altered species isolated will be more difficult with the increased commercialization of new types, he said.
"Plant engineers are moving out of the small plot tests and toward commercialization, therefore the scale of trials is increasing," McCammon said.
Secondary effects on the environment, such as potential harm to threatened or endangered species of plants 
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The Environmental Defense Fund (EDF). an activist group. has called on the FDA to treat new substances in genetically engineered foods as food additives. EDF urged the agency 10 require the same pre-market safety testing for new substances in genetically engineered organisms used for food as is required for food additives.
Labelling of biotech-derived products will be an important issue. Maryanski said. Specific labeling may be needed if, for example. an allergenic part of one food is moved into another food. The label must provide useful information to consumers. he said. but he stated thai it isn't necessary for consumers to know that a product has been "genetically engineered" unless they decide Ihey want that infonnation on the product label.
In the statement to the FDA. the Environmental Defense Fund called for mandatory labeling of genetically engineered foods under existing food ingredient regulations. Describing the existing policy for regulating foods as "outdated." EDF also asked the FDA 10 require labeling of foods with genetically altered characteristics even if the food doesn't contain any new substance as a result of the alteration.
FDA Commissioner David Kessler has said that the agency will present proposals for regulating food products made with biotechnology techniques. but no time frame has been announced. According to a December report in Food Chemical News. the biotechnology company Calgene, inc. has unsuccessfully requested advisory opinions from the FDA on the status of genetically engineered foods. Calgene has been developing genetically engineered tomato, colton, and canola plant varieties for several years.
"Biotechnology in a Global Economy," a study published in October 1991 by the U.S. Congress' Office for Technology Assessment, predicted that food safety would be increasingly important to the public, The study called for FDA regulation of genetically engineered foods, saying that appropriate regulation was critical for New tllJChnlque.en.ble reo.reM,. 10engineer oilseed. wtth specific talty acid protile., consumer confidence in biotechnology-derived foods.
herbicides of the phosphinothricin class. Calgcnc continues to field-test cotton with herbicide resistance. Ten U.S. companies have applied for permission to field-test herbicide-tolerant plant strains. including com, couon. soybean, tomato, alfalfa, and tobacco crops.
The California Biotechnology Action Council and other groups in that state are trying to block commercialization of these herbicide-tolerant plants. Citizens in other states have also spoken out against the introduction of such plants, Several members of Congress imroduced a bill in 1991. named the Herbicide Reduction Act, which would prohibit the use of government funding for research on herbicide-tolerant crops.
Speaking against the idea of restricting government funding was the Council for Agricultural Science and Technology (CAST), a not-forprofit educational organization based in Ames, Iowa. CAST called for a continuation of public spending for research on herbicide resistance, citing "some of the most important fundamental research discoveries of the past decade" as a result of publicly funded research, Not that the U.S. government is spending vast amounts of money on the technology: in 1990 the USDA's Agricultural Research Service (ARS)
iii! Transgenic plants
Many of the biotechnology-related permits have been for transgenic plants, particularly plants engineered to be herbicide-tolerant or to contain toxins 10 particular pests.
Herbicide-to/era", plants
The advent of herbicide-tolerant plants is causing a stir among environmentalists. who fear the unintentional development of equally tolerant weeds and the increased use of herbicides. The environmental and consumer advocates claim that herbicide-tolerant plants will cause farmers to use more herbicides and will lead to herbicide use in areas where none is CUTrently used for fear of damaging a crop. Herbicide-tolerant plants will further increase agriculture's dependence on chemicals, the groups claim. They also fear that altering the genetic make-up of plants could affect nutrient content and toxicity of the foods.
in September and October of 1991, APHIS issued permits to several companies for field tests of herbicide-tolerant crops. Monsanto Agricultural Company is field-testing soybean plants tolerant to the herbicide gtyphosate: The Upjchn Company is testing soybeans and com tolerant to spend $150 million per year on herbicides for this crop. but still lose significant amounts of cotton 10 weeds.
Bromoxyni1 is applied at much lower rates per acre than herbicides traditionally used for cotton. and the chemical breaks down in the soil in a few days. The health effects of bromoxynil are nOI clear. however. and the EPA has ordered further tests on the substance.
Some companies face dual hurdles in bringing a herbicide-resistant crop 10 market because, in addition to winning approval for the plan! variety. they must also gain approval for the herbicide. Getting a new herbicide on the market is expensive. To receive EPA approval, or registration. for a new product a company must undergo a 5-to IO-year regulatory process, costing an estimated $35-50 million. More than 100 tests must be conducted. with detailed documentation.
Because of tightening toxicity stanspent less than $ I00,000 of its budget on developing herbicide-resistant crops. and no ARS projects were exclusively dedicated to that goal. Much more work has been done by the private sector to develop herbicide-resistant crops.
Companies marketing herbicidetolerant plant varieties claim that the new varieties will allow fanners to use reduced amounts or safer herbicides. thereby reducing the amount or chemicals applied to crops and decreasing the residues on foods. Herbicides constitute about two-thirds or all agricultural chemicals used.
Herbicide-tolerant colton developed by Calgene was the first herbicide-tolerant plant variety fer which regulatory approval was sought. The Calgene COli on, engineered to tolerate the herbicide bromoxynil. could reduce the amount or herbicide used on COHon by 60-90%. the company claims. U.S. cotton growers now Manufacturers of small scale screwpresses for more than 50 years.
• Used for production of oil from specialty oil seeds. iii' Biotechnology raises new questions about patents "The PVP Act provides legal protection for self-pollinating species 10 give the same kind of protection available biologically to cross-pollinating species." said Warren Springer. former director of the Minnesota Biotechnology Association. "The earlier legislation was nOI of particular importance to the seed industry because it was directed at asexually propagated species:' PVP certificates are gramed after a plant breeder shows that the variety is novel, unifonn. and stable. Stability means thai the characteristics used to describe the plant must remain stable for at least 18 years, the term of protection. . (BI) used as an applied fungicidel insecticide have been exempted from regulation, but the toxin from the Bt organism. the genetic code of which has been engineered into some plants.
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has nOI been exempted from EPA regulation. The result is the samereduced pests-but the cost to the company is very different.
Bacillus thuringiensis products are derived from a soil bacteria and can be applied directly to crops. or incorporated into the DNA of the crop. so that the plant produces the toxic protein and the insect dies soon after taking a bite of the plant. Monsanto Company and the Agricultural Research Service (ARS) have been successful in their trials with cotton varieties engineered to express the gene-and thus produce the toxin-in plant cells. Cotton is intensively sprayed for pest control: currently. 30-40% of all U.S. insecticide use is on cotton.
Bernice Slutsky. member of the Science Analysis and Coordination Staff at the EPA. spoke on the regulation of transgenic plant pesticides at the July conference. She said that. in assessing the environmental effect of a new pesticide. the EPA considers data about plant characteristics (such as whether there will be out-cropping with any wild relatives). pesticide characteristics. ecological effects. and the potential for toxicity to other insects. For example. if the crop is pollinated by bees. the EPA requires that specific toxicity data be collected to assess the effect of the pesticide on bees. The EPA also requires acute toxicity testing to assess effects of the pesticide on humans. Furthermore, there may be no endangered plant or animal species in a buffer zone around a test site. Slutsky said.
The prospect of target pests developing resistance has tempered optimism for plant pesticides in recent months. The question is whether they are going to remain effective as pesticides over a long term. Entomologists have announced findings that could
Biotechnology raises new questions about patents (conlinut!djrompugt!255J
tion fees for Plant Variety Protection may increase. In September 1991. the Agricultural Marketing Service proposed to increase total fees for processing an application to $2.600 from $2.400. In 1987 the Plant Variety Protection Office was convened to a user-fee trust fund program. in which the fees collected. not tax appropriations, fund the program.
Pan of the controversy surrounding patent protection concerns the permitted exemptions. The philosophy behind the research exemption is that "it will allow us to move ahead." Springer said. "We don't want to have 10 go back to 'ground zero' every time we want to make another improvement in a plant variety."
An exemption allows someone 10 use a protected variety to develop new material without paying a royalty. As long as the material undergoes al least one genetic cross. "you can take a variety and cross it with your own material. then sell the resultant product." Springer said.
Sidney Williams. senior patent counsel at The Upjohn Company. predicted that this exemption will be modified to offer more protection 10 the original patent holder. but he disputed the advisability of curtailing access to new plant varieties. Research exemptions are necessary for milking improvements in plant varieties. he said. and researchers need to know what the patented improvement was in a variety in order to develop even better plants. One can't wait 17 years for a patent to expire before trying to improve again on that plant, Williams said.
Springer said that the crop exemption "works both ways."
Under the exemption. fanners are allowed to grow seed for themselves. and to clean seed for others. "The primary negative aspect has been that it has allowed 'brown bagging: panicularly in seir-pontnaung crops." Springer said.
Farmers who grow enough seed for themselves sometimes sell seed to their neighbors as well. Such cases are difficult to prosecute. Springer said. Fanners don't see anything wrong with this practice, and even if the seed company has a right 10 stop the practice, it isn't considered good company policy to antagonize fanners by trying 10 enforce such rights. he said.
Williams suggested that the law be changed to restrict the amount of seed a farmer could sell.
Springer anticipates a continued effort to define more closely the crop exemption. but he doesn't see the exemption being eliminated altogether. The question is how to modify the exemption to protect companies without huning the individual. he said. If the law is written without sufficient protection to permit a company to recover its investment. there will be no incentive to develop new crop varieties. There's more biotechnology research on soybeans at the university level than by industry. he added. because of the great potential for abuse of the exemption and the tremendous Joss it represents to seed companies. "That's why. in cross-pollinating species. the biologi-prove troubling to companies investing heavily to develop pesticide sprays containing pest toxins. It appears that some insects are able to develop resistance to the Bt toxin, currently being tested for use as an applied insecticide.
Researchers have found that diamondback moths in Hawaii and potato beetles in Florida and New York have developed resistance to insecticide sprays containing the BI rex in. It is unclear if the animals would develop resistance to Bt toxin contained in plant cells. No Bt-produclng plants are on the market yet.
For the Bt toxin to remain an effective pesticide, strategies must be developed and implemented for "resistance management." One way to keep insects from becoming resistant to Bt is to develop genes thai express other insecticidal proteins; insects are less likely to develop resistance 10 both genes. Another issue with the PVP Act is how much public disclosure is required, Springer said. Some portions of the public want to know in great detail what is being altered in the plant, and want to see the data from field experiments, he said, but the PVP Act bars disclosure of information more than one year prior to the application.
"That issue has nor been addressed." Springer said.
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Utility palents Utility patents. available since 1985, offer the most powerful protection available, O'Connor said. Utility patents from the PTa have a 17·year term and cover process, machine, manufacturing, and composition of matter. To qualify for a utility patent, the plant must be new, useful and unobvious. Applications for such a patent must be accompanied by product specifications with full disclosure, and go through a process of protessional examination with payment of appropriate fees, O'Connor said. A utility paten! can cover a number of plant varieties. the gene, and the products derived from the gene. The protection offered by a utility patent is broader than that of plant patents and PVP certificates, and is not limited to a particular variety. A company has the right to exclude Others from making and using its invention, but it also must reveal the invention to others.
Williams described several hurdles in obtaining utility patents: (a) the variety must meet the criteria of "unobviousness"-there must be a clearly inventive step, (b) the application must disclose a complete and "enabling" description of the subject of the patent, and must cover all aspects of its potential use, and (c) the patent cannot infringe on the boundaries of another patent. Every patent has a series of claims. in precise wording. which describe the boundaries of that patent, Williams said.
Acts of paten! infringement include the use of propagating material or harvested material. products made from the harvested material. or products "essentially derived" from the patented material without permission of the patent holder, he said.
Lubrizol Corporalion, the parent company of Agrigenetics Company in Madison, Wisconsin, has received two utility patents on sunflower plants producing seed oil with high oleic acid content, but these patents are under reexamination. Once a patent is issued. other companies may register opposition and have the paten! reexamined by the PTa.
It is not always clear what the PTa will in fact patent. and there is a huge backlog of patents in biotechnology. Agrigenetics Company has applications pending that go back to 1983.
It takes an average of 48 months for a genetically engineered product to receive a patent. In 1990,9,385 biotechnology patent applications were filed.
• Patent laws vary among nations, and U.S. companies are finding that what is patentable in the United States mayor may nor be patentable in other countries.
Biotech companies invest millions of dollars before they see financial returns on those investments. If they are unable 10 patent their inventions. they argue, then other companies who have not done the development work could essentially "steal" the technology and quickly become competitors.
But it isn't just U.S. companies who feel they are gelling ripped off. Some developing nations are claiming that large. multinational companies are stealing their resources 100. The countries claim that large corporations are taking plant varieties from their countries free of charge. improving upon the plants (for example, by encapsulating seed with herbicides or pesticides).
patenting those "improved" varieties. and then selling the seed back to the country of origin with a high price tag-and with no compensation to the country for providing the starting materials. Indeed. more than half of the plants used for the world's food supply originated in the developing nations.
Biotechnology patents are relatively new. In 1985 the U.S. Patent and Trademark Office (PTa) agreed to patent genetically engineered plants; in 1987 the PTO allowed for patenting of nonhuman animals. The United States was the first country to issue a patent on a transgenic animal. in 1988. In the past five years, the patent office has seen a tremendous increase in the number of patent applications. Patents take an average of 26 months for approval in the U.S .
• compared with 43 months in Japan, 28 months in Europe. and 23 months in Canada.
The current Uruguay Round of the GATT talks is the first international trade negotiation to address intellectual property rights. Disagreements exist not only between developing and industrialized countries. but also among the industrialized countries themselves. The United States and Japan say thai all life fonns should be patentable.
with the exception of humans; the European Community delegation to the GAIT has resisted release of engineered organisms did not increase in fiscal year 1990-91.
Despite the recent addition of two biotechnologists. the steadily increasing number of new applications will result in a greater workload of applications per scientist. "We are trying to increase our efficiency," Foudin said. "We are looking to decrease the amount of associated 'paper' by utilizing a computer local area network and streamlining the way we conduct our reviews."
The agency also is looking at ways to increase the efficiency of the regulatory process. although those Changes could take 18-24 months. Foudin was optimistic that APHIS could handle the number of applications expected during the next two years while the system is being improved. The agency also is trying 10 improve information storage and retrieval to speed up the review process.
Managing the workload soon may be the No. J concern of some state agencies. "I have no doubt that the number [nf permit applications] will triple or quadruple in 1992 because of the scientific breakthroughs occurring." Foudin said. "The question is: can the states handle the load?" at APHIS. He reported that in 1991 APHIS received and processed twice as many permits as in 1990 and visited three times more test sites.
"The numbers for 1992 are on target," he said recently. "We will double the number of permits and visit 3-4 times more test sites thnn in 1991. Every year we see a 75-100% increase in applications."
Foudin predicted that the greatest change in future permit applications will be in multi-state, multi-site submissions. which will require more states to be involved with each application.
For the years 1987-1991. Foudin's office issued a total of 171 permits for release of genetically engineered organisms. covering 34 states and Pueno Rico. As of Jan. 22. 1992. the office had received 56 new applications in fiscal year 1992, Of the pennits issued in 1991. 76% were to industry. 13% to universities, and II % to the Agricultural Research Service. Foudin said.
In 1990 APHIS took 90-100 days to process a permit application. he said. Affected states are queried on all applications. and can specify changes in experimental protocol and release conditions. he said. Historically, APHIS has not issued a permit unless it has received concurrence from the state regulatory officials. However, the Supreme Court has consistently ruled in favor of giving USDA preemptive authority on plant quarantine and health matters. Foudin said. Although 81 % of the respondents felt thai social values should be considered along with scientific values, most were also concerned about the effect of public ignorance and misinformation on scienrifle policy. Sixty-eight percent said social scientists. politicians. and religious scholars should not be allowed increased Involvement in decisionmaking on biotechnology issues. Seventy-two percent said ecologists should be included in establishing regulatory policy.
• y" Popular opinion in the U.S. biotech industry is that available protection is not enough. Industrial Biotechnology Association (IRA) president Richard D. Godown told a Senate subcommittee that current advances in biotechnology are threatened by the existing backlog of patent applications, the increase in user fees for patents and trademarks, and the inadequacy of patent protection. The association has also said that it will oppose the North American Free Trade Agreement if Mexico does not modify irs patent laws governing biotechnology, which the IRA says do OOtoffer enough protection 10 inventions.
Warren Springer, former director of the Minnesota Biotechnology Association, said that the current protection available for plant varieties is not adequate. but he cautioned that the development of regulatory policy shouldn't interfere with current rights. Springer held that industry would benefit from regulatory policy that allows maximum protection of research investmern.
eties" may not be patented.
Elizabeth Milewski, special assistant for biotechnology at the EPA, said thai the EPA was trying to harmonize approaches to biotech commercialization between countries. Continuing areas of debate include the scope of the regulations, nomenclature to be adopted for organisms, and descriptors needed for organisms, she reported.
Milewski also cited the need 10 promote free trade. Hannonizing test requirements is another area for international debate, she said, because expensive tests required by certain countries (for example, toxicity tests) could end up being trade inhibitors if the same tests are not required in other countries. Regulators also must agree on acceptable mornods for acquiring data.
Francesco Campagnari spoke at the USDA-APHIS meeting on the European regulations affecting biotechnology; he is a member of the biotechnology section at the European Commission's Joint Research Centre in Milan, Italy. Campagnari reported that an EC Council Directive was adopted in 1990 governing the deliberate release into the environment of genetically modified organisms. The directive requires that an environmental risk assessment be completed before all experimental and subsequent commercial releases of such organisms, Campagnari said. After risk assessment is completed. the directive allows national procedures. subject to EC approval. to regulate experimental releases because of the absence of EC-wide law.
Campagnari said that the EC committee on release of genetically modified organisms is composed of a nonvoting chairman from the European Commission and national representatives with votes proportional to the economic size of the country and its population. Decisions are by qualified majority rule, he said.
The United States and the European Commission have established a task force on biotechnology research. This group originated in 1990 to facilitate the exchange of information and Monslnto ntSelrchers Irs developing oIlseedl which Ire reslsblnt to certlln herbicides or conblln I tOldnto common pests.
The study by Congress' Office for Technology Assessment cautioned that the patent application backlog at the Patent and Trademark Office, uncertainty over patent regulations both in the U.S. and in other countries. and increased patent infringement litigation are areas that could affect the development of biotechnology-derived innovations. The study faulted federal regulation of biotechnology and accused government agencies of falling into disputes over ideology rather than coordinating their activities. These disputes have prevented issuance of final regulations. causing a "regulatory approval process [that] is unclear and inhibits investrneru," the study said.
[jllnternatlonal harmonization
Protecting intellectual property rights abroad is also a concern of U,S, researchers. Sidney Williams. senior patent counsel at The Upjohn Company, reported that an existing international treaty offers interchangeable patent rights for members of the treaty. but that in Europe. "plants" may be patented whereas "plant vari- More than two dozen directives are working their way through a labyrinth of EC departments. Some directives are making European researchers apprehensive, because once adopted the directives would become EC-wide laws, unlike the largely voluntary U.S. protocols governing genetic engineering. EC nations will be required to adopt the approved directives. Overlapping rules and excessive paperwork are anticipated by many European researchers and corporate regulatory advisors.
A major sticking point for the Europeans is that the EC considers genetically engineered organisms a special category of organisms. In contrast, the U.S. Food and Drug Administration (FDA) has chosen not to regulate these organisms differently than it does other organisms. European researchers would like to see the EC apply a "nondiscriminatory" policy toward engineered products, but that isn't considered likely to happen. Laurens Jan Brinkhorst. the director general of the EC's Environment Directorate, was quoted in the June 7, 1991. issue of Science as saying that biotechnology techniques have unique inherent risks that must be considered. He likened biotechnology to nuclear reactors. which like coal and gas facilities produce energy, but have very different risks.
The EC also may require an evaluation of the socioeconomic effects of biotechnology products, the so-called "Founh Hurdle." Socioeconomic evaluations would thus be a part of the formal approval process in addition to present considerations of safety, quality, and efficacy.
Since 1987 the EC has adopted four directives relating to biotechnology. The first directive established a Community-wide approval process for certain drug products; this review process has proven much faster than U.S. approval procedures.
The second directive governs worker safety in biotechnology: it takes effect in 1993 for all states except Portugal, which has until 1995 for implementation.
The third and fourth directives are generating the most controversy. These directives regulate the containment 'and deliberate release of genetically modified organisms; both took effect in October 1991. Regulations concerning deliberate release have been criticized as being too harsh: each release must be approved by an evaluation committee on a case-bycase basis.
One advantage the European system offers over the U.S. approval process is that. once regulations arc established. they are uniform and centralized. In the United States. several agencies (federal or stare or both) are sometimes involved in approval of a single petition. which may prolong the approval process. Another advantage of integration is that once a product is approved by the EC it must be permitted in all the member countries.
For some European countries. "The agricultural community in Utah believes thaI biotechnology is the only way we're going 10 survive," said Miles "Cap" Ferry. Commissioner of Agriculture at the Utah Department of Agriculture.
Speaking at the Third National Confer-r--"--------,,, ence on Federal and Stale Regulation of Biotechnology. Ferry said that the changes offered by biotechnology "ccutdn't be more timely" considering the needs of agricullure in that state. Ferry reported that 75% of the biotechnology research at Utah State University is directed toward agriculture. "we're the second driest stale in the U.S .. and we have very saline soil." Ferry said. "We are looking for alfalfa and other crops that can tolerate salty soils and dry conditions."
Utah fanners also are looking 10 bsxechnology for alternative ways 10 manage weeds and pests. Some chemicals that Utah fanners traditionally have used 10 control weeds and pests soon may be unavailable. Ferry said that using less herbicide, pesticide. and fertilizer would be better for the environment; biotechnological alternatives to chemicals might decrease production COSIS and increase economic returns to fanners. he said.
"Our fanners are very willing 10 accept these changes because they see tbe benefits." Ferry said.
Ultimately. biceechnotogy could increase the rangelands in Utah. Ferry said. Much of the soil in Utah is nitrogen-deficient. and more land would be useable if biotechnology leads to more nitrogen-fixing nonlegumous crops.
"We've never had a recession or depression where agriculture didn't rail first. and we won't get out of it unlil agriculture pulls OUI," he said. "Biotechnology will make agriculture healthier." Bank and former biotechnology manager at the International Service for National Agriculture Research (lSNAR). in The Hague. at a 1991 USDA-APHlS conference on Federal and State Regulation of Biotechnology.
Population in Third World nations is increasing morc rapidly than il is in developed countries, exacerbating their food supply problems. Projected population growth indicates Third World countries will need to double their food supply in the next generation. Persley said. when 90% of the population will live in Third World countries.
The regulatory questions about biotechnology being debated in developed countries-safety. intellectual property rights, and regulation-are not issues in the Third World. Persley said. Biosafety is "not the burning issue" in most of the world, she reported, rather "the No. I priority is better plant varieties and increased yields." Patent questions and disputes aren't important in these countries either: "I don't think the Third World issues (adequate food, hunger) will wait until all the patent questions are resolved." she said. Regulation in such countries probably would not satisfy environmental groups in developed nations, Persley said, but in her view other needs are more important.
"For many countries in the world, the increase in food production is not a luxury. it is a necessity. And when they look at regulation of biotechnology. they do not look at where it is desirable but where it is necessary." she said.
In many nations. very lillie new land is available for food production. meaning that dramatic yield increases will be required. Many countries are looking 10 biotechnology to provide a way to feed their people using available resources.
Persley said. But investment in biotechnology is not occurring to a significant degree in the Third World countries, she said. Some countries do nOI even have existing plant breeding programs. a precursor for biotechnology programs to improve local commodities, Persley reported. Socioeconomic issues will protNFORM. 
